Deliverome uses AI to map the human cell surface and flags 1,108 candidate drug targets

More than 65% of approved medicines work by binding to proteins on the surface of human cells, yet the major biological databases disagree on which proteins are actually there. The Deliverome Project, an open research initiative, used artificial intelligence to review the published evidence and build a map of the human surfaceome, the full set of cell surface proteins.

The map flags 1,108 candidate proteins that are missing from all five major reference databases but are supported by published studies. The findings were posted in October 2026 as a preprint on bioRxiv, so they have not yet been peer reviewed, and the proteins are candidates rather than confirmed targets.

Databases that disagree

The team compared five databases: UniProt, GO CC, the Human Protein Atlas, the Cell Surface Protein Atlas and SURFY. Together they list 5,546 surface proteins, but all five agree on only 188, according to the Hertz Foundation.

How the tool works

Co-founders Becca Carlson and Bobby Hollingsworth developed an artificial intelligence agent powered by the Claude Sonnet 4.6 model. The system examines scientific literature to ascertain if a given protein resides on the cell surface.

On SurfaceBench, a hand-labeled set of 147 proteins, the agent classified 95.7% correctly. UniProt, the best-performing database, scored about 90%.

An example: the KLK2 protein

All five databases classify the protein KLK2 as absent from the cell surface. However, research has found a membrane-anchored form enriched in prostate cancer, and an experimental therapy targeting it is in Phase 3 trials. Deliverome classifies KLK2 as able to appear on the surface under certain conditions.

An open resource

The map is free to explore in Open View, an interactive tool that shows each protein alongside its supporting research. The project also offers a public API and open-source code.

“My hope is that this will help people develop drugs that are more diverse and serve more patients and more indications,” said Carlson, a 2017 Hertz Fellow and the project’s co-CEO.

Deliverome launched on May 27, 2026, backed by $5 million in seed capital originating from the Astera Institute. Operating as a Focused Research Organization, it utilizes a framework tailored to roll out public research instruments inside roughly half a decade. Investigators affiliated with Coral Biosciences additionally contributed as co-authors on the preprint.

References

Anna Edwards

Share
Published by
Anna Edwards

Recent Posts

AI bubble could cause US recession before 2028, former SEC chair Gary Gensler says

The artificial intelligence boom is already a bubble that is likely to burst and push…

1 day ago

How Experian’s RECLAIM documentary reveals the power of financial technology

Data and technology company Experian has released RECLAIM: Stories of Passion and Perseverance, a short…

2 days ago

What a randomized trial tells us about AI and physician diagnostic skills

In a randomised clinical trial published in JAMA Network Open, fifty physicians worked through clinical…

3 days ago

Namibia Breweries and partners commit N$13 million to Swakop Basin water security through new project

Namibia Breweries Limited (NBL), WWF Namibia and Global Water Challenge have signed an agreement to…

3 days ago

How much does World Heritage status increase tourism? Insights from 344 estimates and Italian cases

Winning UNESCO status is almost always defended with a tourism argument. It is the argument…

3 days ago

Jeremy Latcham named new president of DC Studios

James Gunn and Peter Safran will step down from their roles as co-chairs and co-CEOs…

1 week ago